))
Global Blood Therapeutics Commitment to Sickle-Cell Innovation
Manage episode 364016400 series 2838531
内容由RBC Capital Markets提供。所有播客内容（包括剧集、图形和播客描述）均由 RBC Capital Markets 或其播客平台合作伙伴直接上传和提供。如果您认为有人在未经您许可的情况下使用您的受版权保护的作品，您可以按照此处概述的流程进行操作https://zh.player.fm/legal。
In this rebroadcast episode, we flash back to a previous interview with Dr. Ted W. Love, President and CEO of Global Blood Therapeutics (GBT). Dr. Love spoke with our biotechnology analyst Gregory Renza about GBT’s mission-driven culture which led to the development of Oxbryta, the company’s breakthrough sickle-cell treatment, as well as the specific challenges the company faced in tackling a rare orphan disease.
GBT was acquired by Pfizer in October 2022, reinforcing their commitment to sick cell disease and continuing to build on their 30-year legacy in the rare hematology space.
45集单集
分享
